Arendalsuka 2026

Norway’s current procurement and pricing models in health are largely optimized for short-term cost efficiency. Mechanisms such as strict price competition drive prices down, but overlook broader value contributions from pharmaceutical and MedTech companies. At the same time, industry contributes far beyond just products: R&D, local competence, industrial presence, support to patient organizations, and resilient supply chains are also deeply relevant. These contributions are not systematically captured and valued in today’s frameworks.

Questions that will be addressed:

What can the healthcare sector learn from defense procurements and long-term partnerships? Which elements are transferable, and where are the differences too significant? How can policy and procurement frameworks support both predictability for investment and stronger national and regional preparedness, while preserving patient access?

Read more HERE.